STING1 and neoplasm: TLR7/8 agonists (imidazoquinolines), TLR9 agonists (synthetic CpG oligonucleotides) and STING agonists (cyclic di-nucleotides) have all shown potent anti-tumor activity in a range of murine cancer models [4].